These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
257 related articles for article (PubMed ID: 23406816)
21. Modelling the cost-effectiveness of catch-up 'MenB' (Bexsero) vaccination in England. Christensen H; Trotter CL Vaccine; 2017 Jan; 35(2):208-211. PubMed ID: 27923519 [TBL] [Abstract][Full Text] [Related]
22. Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study. Parikh SR; Andrews NJ; Beebeejaun K; Campbell H; Ribeiro S; Ward C; White JM; Borrow R; Ramsay ME; Ladhani SN Lancet; 2016 Dec; 388(10061):2775-2782. PubMed ID: 28100432 [TBL] [Abstract][Full Text] [Related]
23. Public Health Impact and Cost-Effectiveness Analysis of Routine Infant 4CMenB Vaccination in Germany to Prevent Serogroup B Invasive Meningococcal Disease. Scholz S; Schwarz M; Beck E; Meszaros K; Schneider M; Ultsch B; Greiner W Infect Dis Ther; 2022 Feb; 11(1):367-387. PubMed ID: 34877641 [TBL] [Abstract][Full Text] [Related]
24. 'Be on the TEAM' Study (Teenagers Against Meningitis): protocol for a controlled clinical trial evaluating the impact of 4CMenB or MenB-fHbp vaccination on the pharyngeal carriage of meningococci in adolescents. Carr J; Plested E; Aley P; Camara S; Davis K; MacLennan JM; Gray S; Faust SN; Borrow R; Christensen H; Trotter C; Maiden MCJ; Finn A; Snape MD; BMJ Open; 2020 Oct; 10(10):e037358. PubMed ID: 33093030 [TBL] [Abstract][Full Text] [Related]
25. The introduction of the meningococcal B (MenB) vaccine (Bexsero®) into the national infant immunisation programme--New challenges for public health. Ladhani SN; Campbell H; Parikh SR; Saliba V; Borrow R; Ramsay M J Infect; 2015 Dec; 71(6):611-4. PubMed ID: 26433141 [TBL] [Abstract][Full Text] [Related]
26. Meningococcal group B vaccines. Findlow J Hum Vaccin Immunother; 2013 Jun; 9(6):1387-8. PubMed ID: 23732894 [TBL] [Abstract][Full Text] [Related]
27. Potential Coverage of the 4CMenB Vaccine against Invasive Serogroup B Mulhall RM; Bennett D; Cunney R; Borrow R; Lucidarme J; Findlow J; Jolley KA; Bray J; Maiden MCJ; Moschioni M; Serino L; Stella M; Medini D mSphere; 2018 Aug; 3(4):. PubMed ID: 30135218 [No Abstract] [Full Text] [Related]
28. Public Health Impact and Cost-Effectiveness Analysis of 4-Component Meningococcal Serotype B Vaccination for Infants in France. de Pouvourville G; Breau-Brunel M; Loncle-Provot V; Beck E; Gaugain L; Nachbaur G; Pribil C Pharmacoecon Open; 2024 Jul; 8(4):539-557. PubMed ID: 38780884 [TBL] [Abstract][Full Text] [Related]
29. Vaccinating adolescents against meningococcal disease in Canada: a cost-effectiveness analysis. De Wals P; Coudeville L; Trottier P; Chevat C; Erickson LJ; Nguyen VH Vaccine; 2007 Jul; 25(29):5433-40. PubMed ID: 17560695 [TBL] [Abstract][Full Text] [Related]
30. [Economic evaluation of the introduction of 4CMenB (Bexsero®) in the national vaccine schedule in Spain]. Ruiz-Montero R; Epstein D; Guzmán Herrador B; Espín Balbino J Gac Sanit; 2020; 34(4):318-325. PubMed ID: 31776044 [TBL] [Abstract][Full Text] [Related]
31. Protecting UK adolescents and adults against meningococcal serogroup B disease. Vyse A; Ellsbury G; Madhava H Expert Rev Vaccines; 2018 Mar; 17(3):229-237. PubMed ID: 29374982 [TBL] [Abstract][Full Text] [Related]
32. Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage. Frosi G; Biolchi A; Lo Sapio M; Rigat F; Gilchrist S; Lucidarme J; Findlow J; Borrow R; Pizza M; Giuliani MM; Medini D Vaccine; 2013 Oct; 31(43):4968-74. PubMed ID: 23954380 [TBL] [Abstract][Full Text] [Related]
33. Outcomes of meningococcal serogroup B disease in children after implementation of routine infant 4CMenB vaccination in England: an active, prospective, national surveillance study. Mensah AA; Campbell H; Clark SA; Ribeiro S; Lucidarme J; Bai X; Borrow R; Ladhani SN Lancet Child Adolesc Health; 2023 Mar; 7(3):190-198. PubMed ID: 36736341 [TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of alternative strategies for vaccination of adolescents against serogroup B IMD with the MenB-FHbp vaccine in Canada. Breton MC; Huang L; Snedecor SJ; Cornelio N; Fanton-Aita F Can J Public Health; 2020 Apr; 111(2):182-192. PubMed ID: 31907760 [TBL] [Abstract][Full Text] [Related]
35. Potential impact of vaccination against Neisseria meningitidis on Neisseria gonorrhoeae in the United States: results from a decision-analysis model. Régnier SA; Huels J Hum Vaccin Immunother; 2014; 10(12):3737-45. PubMed ID: 25483706 [TBL] [Abstract][Full Text] [Related]
36. Cost calculator for mass vaccination response to a US college campus outbreak of serogroup B meningococcal disease. La EM; Talbird SE; Kanadanian KV; Huang L; Fain J; Srivastava A Hum Vaccin Immunother; 2019; 15(4):978-986. PubMed ID: 30526279 [TBL] [Abstract][Full Text] [Related]
37. Commentary: European Medicines Agency recommends approval of a broadly protective vaccine against serogroup B meningococcal disease. Granoff DM Pediatr Infect Dis J; 2013 Apr; 32(4):372-3. PubMed ID: 23263177 [No Abstract] [Full Text] [Related]
38. Cost-effectiveness of vaccination of the elderly against herpes zoster in The Netherlands. de Boer PT; Pouwels KB; Cox JM; Hak E; Wilschut JC; Postma MJ Vaccine; 2013 Feb; 31(9):1276-83. PubMed ID: 23306360 [TBL] [Abstract][Full Text] [Related]
39. Clinical data supporting a 2-dose schedule of MenB-FHbp, a bivalent meningococcal serogroup B vaccine, in adolescents and young adults. Beeslaar J; Absalon J; Balmer P; Srivastava A; Maansson R; York LJ; Perez JL Vaccine; 2018 Jun; 36(28):4004-4013. PubMed ID: 29861182 [TBL] [Abstract][Full Text] [Related]
40. Parental awareness and utilization of meningococcal serogroup B vaccines in the United States. Srivastava A; Dempsey A; Galitsky A; Fahimi M; Huang L BMC Public Health; 2020 Jul; 20(1):1109. PubMed ID: 32664872 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]